Cheaper keytruda? new biosimilar SB27 tested in lung cancer
NCT ID NCT06348199
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 4 times
Summary
This phase 3 trial tests whether SB27, a proposed biosimilar to the cancer drug Keytruda, works as well as the original in people with advanced non-squamous non-small cell lung cancer. About 555 participants will receive either SB27 or Keytruda plus chemotherapy every 3 weeks. The main goal is to compare tumor shrinkage rates at 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SB27 (a proposed biosimilar to pembrolizumab, the drug in Keytruda)
- What this could lead to
- If SB27 works as well as Keytruda, it could offer a more affordable treatment option for advanced lung cancer patients.
- What could go wrong
- This is a biosimilar study, not a new drug. Even if SB27 matches Keytruda, it may not improve outcomes. The trial is still ongoing, and results are not yet available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER STAGE IV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
SB Investigative Site
Banja Luka, Bosnia and Herzegovina
-
SB Investigative Site
Mostar, Bosnia and Herzegovina
-
SB Investigative Site
Sarajevo, Bosnia and Herzegovina
-
SB Investigative Site
Curitiba, Brazil
-
SB Investigative Site
Florianópolis, Brazil
-
SB Investigative Site
Ijuí, Brazil
-
SB Investigative Site
Natal, Brazil
-
SB Investigative Site
Pelotas, Brazil
-
SB Investigative Site
Rio de Janeiro, Brazil
-
SB Investigative Site
Santo André, Brazil
-
SB Investigative Site
Batumi, Georgia
-
SB Investigative Site
Düsseldorf, Germany
-
SB Investigative Site
Halle, Germany
-
SB Investigative Site
Moers, Germany
-
SB Investigative Site
Neuss, Germany
-
SB Investigative Site
Bangalore, India
-
SB Investigative Site
Bhubaneswar, India
-
SB Investigative Site
Erandwane, India
-
SB Investigative Site
Hyderabad, India
-
SB Investigative Site
Mumbai, India
-
SB Investigative Site
Sūrat, India
-
SB Investigative Site
Udaipur, India
-
SB Investigative Site
Himeji, Japan
-
SB Investigative Site
Iwakuni, Japan
-
SB Investigative Site
Izumi, Japan
-
SB Investigative Site
Kawachi-Nagano, Japan
-
SB Investigative Site
Kobe, Japan
-
SB Investigative Site
Kochi, Japan
-
SB Investigative Site
Sagamihara, Japan
-
SB Investigative Site
Tachikawa, Japan
-
SB Investigative Site
Takarazuka, Japan
-
SB Investigative Site
Toyonaka, Japan
-
SB Investigative Site
George Town, Malaysia
-
SB Investigative Site
Johor Bahru, Malaysia
-
SB Investigative Site
Kota Bharu, Malaysia
-
SB Investigative Site
Kuantan, Malaysia
-
SB Investigative Site
Lembah Pantai, Malaysia
-
SB Investigative Site
Putrajaya, Malaysia
-
SB Investigative Site
Aguascalientes, Mexico
-
SB Investigative Site
Guadalajara, Mexico
-
SB Investigative Site
Mexico City, Mexico
-
SB Investigative Site
Davao City, Philippines
-
SB Investigative Site
Makati City, Philippines
-
SB Investigative Site
Manila, Philippines
-
SB Investigative Site
Quezon City, Philippines
-
SB Investigative Site
San Juan City, Philippines
-
SB Investigative Site
Cluj-Napoca, Romania
-
SB Investigative Site
Craiova, Romania
-
SB Investigative Site
Iași, Romania
-
SB Investigative Site
Oradea, Romania
-
SB Investigative Site
Sibiu, Romania
-
SB Investigative Site
Suceava, Romania
-
SB Investigative Site
Kamenitz, Serbia
-
SB Investigative Site
Kragujevac, Serbia
-
SB Investigative Site
Niš, Serbia
-
SB Investigative Site
Leganés, Spain
-
SB Investigative Site
Málaga, Spain
-
SB Investigative Site
Ourense, Spain
-
SB Investigative Site
Oviedo, Spain
-
SB Investigative Site
Santiago de Compostela, Spain
-
SB Investigative Site
Seville, Spain
-
SB Investigative Site
Valencia, Spain
-
SB Investigative Site
Bangkok Noi, Thailand
-
SB Investigative Site
Khon Kaen, Thailand
-
SB Investigative Site
Adapazarı, Turkey (Türkiye)
-
SB Investigative Site
Bağcılar, Turkey (Türkiye)
-
SB Investigative Site
Balgat, Turkey (Türkiye)
-
SB Investigative Site
Çubuk, Turkey (Türkiye)
-
SB Investigative Site
Istanbul, Turkey (Türkiye)
-
SB Investigative Site
İzmit, Turkey (Türkiye)
-
SB Investigative Site
Kavaklıdere, Turkey (Türkiye)
-
SB Investigative Site
Konak, Turkey (Türkiye)
-
SB Investigative Site
Maltepe, Turkey (Türkiye)
-
SB Investigative Site
Seyhan, Turkey (Türkiye)
-
SB Investigative Site
Sivas, Turkey (Türkiye)
-
SB Investigative Site 1
Porto Alegre, Brazil
-
SB Investigative Site 1
Tbilisi, Georgia
-
SB Investigative Site 1
Jaipur, India
-
SB Investigative Site 1
Craiova, Romania
-
SB Investigative Site 1
Belgrade, Serbia
-
SB Investigative Site 1
Bangkok, Thailand
-
SB Investigative Site 1
Ankara, Turkey (Türkiye)
-
SB Investigative Site 2
Porto Alegre, Brazil
-
SB Investigative Site 2
Tbilisi, Georgia
-
SB Investigative Site 2
Jaipur, India
-
SB Investigative Site 2
Craiova, Romania
-
SB Investigative Site 2
Belgrade, Serbia
-
SB Investigative Site 2
Bangkok, Thailand
-
SB Investigative Site 2
Ankara, Turkey (Türkiye)
-
SB Investigative Site 3
Tbilisi, Georgia
-
SB Investigative Site 4
Tbilisi, Georgia
-
SB Investigative Site 5
Tbilisi, Georgia
-
SB Investigative Site 6
Tbilisi, Georgia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental lung cancer vaccine trial halted early
- New radioactive drug targets Hard-to-Treat cancers in early trial
- New triple therapy aims to slow advanced lung cancer
- New test aims to match lung cancer patients with best therapy
- New hope for frail lung cancer patients: immunotherapy drug tested
- New hope for patients with rare brain lining cancer spread